J&J MedTech announced today the U.S. launch of the VOLT™ Plating System. The launch of this system represents an evolution in fracture management designed to improve stability, enhance performance, and increase efficiency.
Smith+Nephew and JointVue signed a co-marketing agreement for OrthoSonic 3D surgery planning technology. The technology allows surgeons using the Smith & Nephew Cori surgical robot to create personalized knee arthroplasty procedure plans.
What are the essentials for compliant claims? How do you support and monitor claims in packaging and promotional content? Creating and following internal procedures is a strong defense.
Five startups selected to participate in Memphis area Accelerator following The comprehensive 13-week go-to-market program is specifically designed to support medtech startups through essential business development stages.
MTI Regulatory Report 2024 data overwhelmingly suggests regulatory resources throughout the industry are being stretched. Time/Bandwidth is the top medical device regulatory challenge faced during 2024, potentially leading to industry-wide regulatory fatigue and driven by changing global compliance regulations in recent years.
The MDIC Annual Public Forum 2024 kicked off this week with experts from the National Evaluation System for health Technology (NEST), the Centers for Medicare and Medicaid Services (CMS), and the FDA. Topics included the future of real-world evidence (RWE) and the integration of AI into the healthcare ecosystem and how can we leverage emerging technologies to bring innovative and safer solutions to patients.
Embecta’s insulin delivery system gains FDA nod | Aidoc’s AI algorithms for CT scans secure CE mark | Medtronic Has Positive Long-Term Extravascular ICD Study Data | And more news of ThisWeek in MedTech.
MedTech organizations need to focus on the human factor of change and achieve top-down alignment, buy-in, accountability, and clear communication along the way.
Recently, biocompatibility consultant, MedTech enthusiast and chemist, Marina Daineko, shared a series of LinkedIn posts defining, medical device biocompatibility and the need for a Medical Device biological risk assessment “framework.” Following is a reposting of Marina’s original LinkedIn series.
In the light of new research, Peter Muller and Mike Baird of Schlafender Hase assess how well Class 2 and 3 device manufacturers in Europe and the US are adapting to a rise in regulatory controls.
